Scientists say threat posed by measles is ‘much greater than we previously imagined’Measles causes long-term damage to the immune system, leaving children who have had it vulnerable to other infections long after the initial illness has passed, research has revealed.Two studies of unvaccinated children in an Orthodox Protestant community in the Netherlands found that measles wipes out the immune system ’s memory of previous illnesses, returning it to a more baby-like state, and also leaves the body...
Thu Oct 31, 2019 19:00
(Source: ScienceNOW)
Thu Oct 31, 2019 00:00
Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens
Measles virus is directly responsible for more than 100,000 deaths yearly. Epidemiological studies have associated measles with increased morbidity and mortality for years after infection, but the reasons why are poorly understood. Measles virus infects immune cells, causing acute immune suppression. To identify and quantify long-term effects of measles on the immune system, we used VirScan, an assay that tracks antibodies to thousands of pathogen epitopes in blood. We studied 77 unvaccinated children...
Thu Oct 31, 2019 00:00
If there is anything worse than bragging about one's charitable giving, it is bragging about the charitable giving one might accomplish in the future, should one turn out to have the funds to do so. In a world in which establishing cultural norms wasn't so very important to success in non-profit fundraising, none of the audience here would know anything about my donations to the Methuselah Foundation and SENS Research Foundation, made over the years as we moved ever closer to the reality of therapies...
Thu Oct 31, 2019 17:00
Transformations aren’t just for people or pets around Halloween. Scientific images also can look different than you might expect, depending on how they’re photographed. Check out these tricky-looking images and learn more about the science behind them. Credit: Nilay Taneja, Vanderbilt University, and Dylan T. Burnette, Ph.D., Vanderbilt University School of Medicine. Do you have a hunch about what this image is? Perhaps something to do with dry leaves? It’s a human...
Thu Oct 31, 2019 14:06
GAITHERSBURG, Md., Oct. 31, 2019 -- (Healthcare Sales & Marketing Network) -- The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) granted Shreis Scalene Sciences (Shreis), in Gaithersburg, MD, 'Breakthrough... Devices, Oncology, FDA Shreis Scalene Sciences, CYTOTRON, Quantum Magnetic Resonance (Source: HSMN NewsFeed)
Thu Oct 31, 2019 14:21
THURSDAY, Oct. 31, 2019 -- For individuals with obesity, bariatric surgery is associated with a reduced risk for skin cancer, including melanoma, according to a study published online Oct. 30 in JAMA Dermatology. Magdalena Taube, Ph.D., from the... (Source: Drugs.com - Pharma News)
Thu Oct 31, 2019 13:00
THURSDAY, Oct. 31, 2019 -- For older patients with ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery (BCS), sentinel lymph node biopsy (SLNB) is not associated with improvements in long-term outcomes, according to a study... (Source: Drugs.com - Pharma News)
Thu Oct 31, 2019 13:00
Boehringer Ingelheim presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA(1). Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid tumors with KRAS mutations. (Source: World Pharma News)MedWorm Message: Have you tried...
Thu Oct 31, 2019 10:00
Publication date: Available online 30 October 2019Source: Journal of Vascular and Interventional RadiologyAuthor(s): Stephan Walrand, Carlo Chiesa, Pablo Minguez Gabina, Nicolas Chouin, Jonathan Gear, Caroline Stokke, Peter Bernhardt, Katarina Sjogreen Gleisner, Lidia Strigari, Mark Konijnenberg, EANM Dosimetry Committee (Source: Journal of Vascular and Interventional Radiology)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media...
03:16
ConclusionPercutaneous osteoplasty is a safe and effective choice for patients with painful osteolytic pelvic bone metastases. It can relieve pain, reduce disability, and improve function.Level of EvidenceLevel 3b, retrospective study. (Source: CardioVascular and Interventional Radiology)
03:14
ConclusionsCBCT for renal ablation guidance is a viable tool. Larger series are needed to compare it to MDCT. (Source: CardioVascular and Interventional Radiology)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
03:14
ConclusionsEarly warning models were proposed to predict the risk of 30-day mortality after PTBS in patients with MBO. The ANN model has higher accuracy and better generalizability than the logistic model. (Source: CardioVascular and Interventional Radiology)
03:14
ConclusionLiMAx is capable of detecting changes in liver function, even modulations caused by superselective TACE procedures. Accordingly, it could be used as a tool for patient selection and monitoring of transarterial therapy. In comparison, Child –Pugh and ALBI scores did not reflect any of these changes. Some biochemical parameters also changed significantly after TACE, but they tend to be less specific in providing sufficient information on actual cellular dysfunction. (Source: CardioVascular...
03:14
ConclusionPV is long-term effective for consolidation of VM and must be discussed at the early diagnosed. Quality of cement injection matters, suggesting that techniques that improve the quantity and the quality of cement diffusion into the VM must be developed. (Source: CardioVascular and Interventional Radiology)
03:14
Authors: Palmieri A, Scapoli L, Iapichino A, Mercolini L, Mandrone M, Poli F, Giannì AB, Baserga C, Martinelli M Abstract Berberine (BBR) is a natural active principle with potential antitumor activity. The compound targets multiple cell signaling pathways, including proliferation, differentiation, and epithelial-mesenchymal transition. The aim of this study was to elucidate the mechanisms behind the anticancer activity of BBR by comparing the effects of purified BBR with those of the extract...
03:11
ConclusionOur findings affirm that hysteroscopy does not compromise the survival of patients with early-stage endometrial cancer. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
02:06
ConclusionOur study suggests that interest in uterine fibroids has increased since the FDA statement, but the public are perhaps unaware or not concerned of the consequent potential risk of leiomyosarcoma following morcellation. Countries where fibroid interest is highest are not necessarily those that can offer power morcellation. Further studies are required to address how the Internet influences patient choice and informed consent, and how medical professionals can use it to further educate patients...
02:06
Publication date: Available online 31 October 2019Source: Journal of Functional FoodsAuthor(s): Craig S. Charron, Janet A. Novotny, Elizabeth H. Jeffery, Matthew Kramer, Sharon A. Ross, Harold E. SeifriedAbstractBrassica vegetables may modulate cancer risk by regulation of xenobiotic metabolizing enzymes (XMEs). In a randomized crossover study, the effect of kale consumption on CYP1A2, CYP2A6, XO, and NAT2 activity was determined by urinary caffeine metabolite ratios, UGT1A1 activity by serum bilirubin...
02:03
Publication date: Available online 31 October 2019Source: Journal of Functional FoodsAuthor(s): Luoyang Wang, Nan Jing, Xuerun Liu, Guoqiang Jiang, Zheng LiuAbstractThe discovery that gut microbiota profoundly influences the efficiency of immune checkpoint blockade therapy in patients inspired the efforts to enhance cancer treatment using live microorganisms to modify gut microbiome. Here we present a new idea of modifying gut microbiota to enhance anti-PD-L1 efficiency, that is, using natural nutrients....
02:03
Conclusions: The low proportion of older patients undergoing treatment with curative intent, despite no or limited comorbidity, indicates missed chances of treatment with curative intent. The reasons for an overall decrease in curative treatment over time need to be analysed and the challenge of coping with an increasing proportion of node-positive patients with clinically significant comorbidity needs to be met. PMID: 31663405 [PubMed - as supplied by publisher] (Source: Scandinavian Journal...
02:01
Conclusion: The association between education and first-time PSA testing indicates socioeconomic disparities in health care utilisation, which could explain part of the observed socioeconomic difference in prostate cancer incidence and mortality. PMID: 31663414 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Urology)
02:01
CONCLUSION: Our study demonstrated that a number of different specialties outside of dermatology are involved in performing biopsies on patients in which melanoma is a concern. Although the results show that the majority of patients biopsied by non-dermatologists received appropriate follow-up care, there is still room to improve to ensure that all melanoma patients receive referrals to and are seen by dermatologists after a diagnosis of melanoma. PMID: 31665406 [PubMed - as supplied by publisher]...
01:51
This study intends to determine the prevalence of EBV in gastric dysplasia and superficial neoplasia to clarify whether EBV infection is an early or late event in gastric cancer development. This retrospective study included a total of 242 gastric lesions from 199 consecutive patients who were referred for endoscopic resection. The histological classification of lesions includes 137 low- and high-grade dysplasia and 105 superficial carcinomas. EBV infection was investigated by EBER-ISH. Results showed...
00:00
(Source: MRC Funding Opportunities)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
03:40
Condition: Head and Neck Squamous Cell Carcinoma Intervention: Drug: PD-1 Sponsor: Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Conditions: Non-Small Cell Lung Cancer; ALK Gene Rearrangement Positive Intervention: Drug: Ensartinib Sponsor: Xcovery Holding Company, LLC Available (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Thu Oct 31, 2019 17:00
Condition: Frailty Intervention: Sponsor: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Conditions: Advanced Renal Cell Carcinoma (All Subtypes); Metastatic Renal Cell Carcinoma (All Subtypes) Intervention: Other: Documentation Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Condition: Genetic Predisposition to Disease Interventions: Genetic: BRIDGES gene panel testing; Genetic: Breast cancer risk polygenic risk score (PRS); Behavioral: Questionnaires Sponsor: Institut Curie Recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Condition: Head and Neck Cancer Interventions: Behavioral: Yoga Video; Behavioral: Posture and Strengthening Video; Behavioral: Relaxation Video; Behavioral: Breath Work Video; Behavioral: Satisfaction Survey; Behavioral: Guided Yoga Session; Behavioral: Written Yoga Instructions Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Condition: Breast Cancer Intervention: Sponsor: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Condition: Carcinoma, Pancreatic Ductal Interventions: Combination Product: SonoVue; Drug: Chemotherapy Sponsors: St. Olavs Hospital; Norwegian University of Science and Technology Not yet recruiting (Source: ClinicalTrials.gov)
Thu Oct 31, 2019 17:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου